New Leaf Venture Partners Archives

CuraSen appoints Kathleen Sereda Glaub as Chair of its Board alongside Dr Anthony Ford as CEO and announces $54.5m Series A financing led by New Leaf Venture Partners

October 18, 2018October 17, 2018

– USA, CA – CuraSen Therapeutics, Inc., a privately held biotechnology company focused on developing therapies to treat neurodegenerative diseases, today announced the closing of a $54.5 million Series A financing led by New Leaf Venture Partners, the investor syndicate includes Longitude Capital, funds managed by Tekla Capital Management LLC, Alta Partners, Johnson & Johnson Innovation – JJDC, Inc.…

Harpoon Therapeutics announces Mark Chin and Ron Hunt to its Board along with raising $45m Series B financing co-led by Arix Bioscience and New Leaf Venture Partners

October 27, 2021May 25, 2017

– USA, CA – Harpoon Therapeutics, a biotechnology company developing novel T-cell recruiting biologic therapies for the treatment of cancer, today announced the completion of a $45M Series B financing, which included Arix Bioscience, New Leaf Venture Partners and Taiho Ventures, who are all new investors in the company, and existing investor MPM Capital.…

Aptinyx strengthens its Board along with a $65m Series A financing led by New Leaf Venture Partners

May 11, 2021May 10, 2016

– USA, IL – Aptinyx Inc., a biopharmaceutical company developing novel modulators of the N-methyl-D-aspartate (NMDA) receptor for the treatment of challenging neurological disorders, today announced the completion of a $65 million Series A financing.…

AiCure adds Vijay Lathi to its Board along with closing a $12.25m Series A funding round led by New Leaf Venture Partners

January 13, 2016January 11, 2016

– USA, NY – AiCure, an artificial intelligence company connecting the world’s patients to better treatments and improved health, has closed a Series A fundraising round with $12.25 million.…

Arvinas closed a $41.6m Series B financing round and appoints 3 New Board Members

November 30, 2016October 21, 2015

– USA, CT – Arvinas LLC a private biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that it has closed a Series B financing round of $41.6 million.…